NCT03392571View on ClinicalTrials.gov

Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 15, 2018

Primary Completion Date

December 30, 2020

Study Completion Date

December 30, 2020

Conditions
Resectable Pancreatic Cancer
Interventions
DRUG

NGC-Triple regimen

gemcitabine 800 mg/m2; Abraxane (nab-paclitaxel 100 mg/m2; cisplatin 25 mg/m2

Sponsors

Collaborators (1)

Celgene
All Listed Sponsors
collaborator

Celgene

INDUSTRY

lead

Pancreatic Cancer Research Team

OTHER

NCT03392571 - Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients | Biotech Hunter | Biotech Hunter